Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Japan OKs 2021 Fiscal Policy Blueprint, Vows Transparency in Drug Pricing
Japan’s Cabinet approved the 2021 Basic Policy for Economic and Fiscal Management and Reform (honebuto) on June 18, finalizing a revision to its original draft that added a line to call for “transparency and predictability” in the drug pricing system.…
To read the full story
Related Article
- Japan Govt to Accelerate Discussion on Specific Growth Strategy
September 3, 2021
- Honebuto Text to Add Line for “Transparency and Predictability” of Drug Pricing System
June 16, 2021
- LDP Flags 80% Generic Target for All Prefectures: Honebuto Debate
June 11, 2021
- Govt Unveils Draft Honebuto Paper for 2021, Cabinet OK Expected after Party Tweaks
June 10, 2021
- Japan Aims for 80% Generic Share in All Prefectures by FY2023-End: Honebuto Draft
June 9, 2021
- Japan to Establish Ecosystem to Deliver Innovative Drugs: Draft Growth Strategy
June 3, 2021
REGULATORY
- War-Linked Supply Concerns Rise to 43 Cases, Focus Shifts to Solvents, Packaging
April 24, 2026
- JPMA Pushes for “Freeze” on On-Patent Drug Price Cuts at LDP Meeting
April 23, 2026
- MHLW to Exclude High School-Age and Younger from OTC-Like Drug Charge: Official
April 23, 2026
- Japan, Singapore to Share GMP Inspection Results under Cooperation Pact
April 23, 2026
- MHLW Orders Label Revisions for Remicade, Enbrel, Bavencio, and More Drugs
April 22, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…